Metropolis Healthcare FY26 Earnings Surge: Profit Jumps 31% to ₹191 Cr on Record Revenue

Metropolis Healthcare's consolidated annual profit for FY26 surged 31.38% to ₹191.18 crore, up from ₹145.51 crore in the previous year.
Consolidated revenue for the full year reached a record ₹1,671.43 crore, marking a significant 24.15% increase from FY25.
Reader Takeaway: Growth fuelled by acquisitions and core business expansion; ₹38.8 Cr tax demand a key watch point.

What just happened (today’s filing)

Metropolis Healthcare reported strong financial results for the quarter and year ended March 31, 2026.

On a consolidated basis, the company's total income for Q4 FY26 stood at ₹432.84 crore, with a profit of ₹50.96 crore and EPS of ₹2.46.

For the full fiscal year FY26, consolidated income grew 24.15% to ₹1,671.43 crore, while profit increased by 31.38% to ₹191.18 crore. Basic EPS was ₹9.19.

Standalone results also showed growth, with FY26 income at ₹1,381.80 crore and profit at ₹157.48 crore.

The company also declared a second interim dividend of ₹1 per share for FY26 and successfully completed acquisitions of Dapic and Scientific Metropolis.

Why this matters

These results demonstrate robust growth in Metropolis Healthcare's core pathology business, driven by strategic acquisitions and operational efficiency.

The profit jump and revenue expansion signal a strengthening market position in the competitive diagnostics sector.

Declaration of a dividend rewards shareholders, while acquisitions pave the way for future expansion and service diversification.

The backstory (grounded)

The company is facing an ongoing income tax demand of ₹38.8 crore. This arose following searches conducted by the Income Tax Department, with the demand currently under appeal at the ITAT.

Metropolis Healthcare has been actively pursuing inorganic growth, recently completing acquisitions of Dapic and Scientific Metropolis to bolster its market presence and service offerings.

What changes now

Shareholders will receive a ₹1 per share interim dividend, providing direct returns.

The successful integration of recent acquisitions, Dapic and Scientific Metropolis, will be crucial for sustained growth.

Investor focus will remain on the resolution pathway for the ₹38.8 crore income tax demand.

Operational efficiencies and market penetration are expected to continue driving EPS growth.

Risks to watch

An income tax demand of ₹38.8 crore remains under appeal at the ITAT, presenting a potential financial overhang.

An exceptional expense of ₹8.99 crore was recorded in consolidated results due to the statutory impact of new Labour Codes.

Peer comparison

Metropolis Healthcare's FY26 revenue of ₹1,671.43 crore and profit of ₹191.18 crore show strong momentum.

Competitor Dr. Lal PathLabs reported FY24 revenue of approx. ₹1,931 crore and profit of ₹217 crore, indicating a competitive landscape where Metropolis is narrowing the scale gap.

Vijaya Diagnostic Centre, a smaller peer, reported FY24 revenue of approx. ₹848 crore and profit of ₹172 crore.

Context metrics (time-bound)

• Consolidated income for FY26 reached ₹1,671.43 crore.
• Consolidated profit for FY26 was ₹191.18 crore.
• Q4 FY26 consolidated income grew 22.88% year-on-year.
• FY26 consolidated income grew 24.15% year-on-year.

What to track next

• Management commentary on the integration of Dapic and Scientific Metropolis acquisitions.
• Updates on the progress of the income tax appeal.
• The ongoing impact of new Labour Codes on operating expenses.
• Future dividend declarations and capital allocation plans.
• Competitive responses and market share trends in the diagnostics sector.
• Any further strategic partnership or acquisition announcements.